Search Results

There are 2890 results for: content related to: Combination Angiotensin Receptor Blocker-Neutral Endopeptidase Inhibitor Provides Additive Blood Pressure Reduction Over Angiotensin Receptor Blocker Alone

  1. Neprilysin Inhibition in Heart Failure with Reduced Ejection Fraction: A Clinical Review

    Pharmacotherapy: The Journal of Human Pharmacology and Drug Therapy

    Volume 35, Issue 9, September 2015, Pages: 823–837, Jordan B. King, Adam P. Bress, Austin D. Reese and Mark A. Munger

    Version of Record online : 25 SEP 2015, DOI: 10.1002/phar.1629

  2. Renin–Angiotensin–Aldosterone System Inhibitors in Heart Failure

    Clinical Pharmacology & Therapeutics

    Volume 94, Issue 4, October 2013, Pages: 459–467, F Shearer, C C Lang and A D Struthers

    Version of Record online : 12 JUL 2013, DOI: 10.1038/clpt.2013.135

  3. You have free access to this content
    Neprilysin inhibition to treat heart failure: a tale of science, serendipity, and second chances

    European Journal of Heart Failure

    Volume 17, Issue 3, March 2015, Pages: 242–247, John J.V. McMurray

    Version of Record online : 9 MAR 2015, DOI: 10.1002/ejhf.250

  4. You have full text access to this OnlineOpen article
    Dual angiotensin receptor and neprilysin inhibition as an alternative to angiotensin-converting enzyme inhibition in patients with chronic systolic heart failure: rationale for and design of the Prospective comparison of ARNI with ACEI to Determine Impact on Global Mortality and morbidity in Heart Failure trial (PARADIGM-HF)

    European Journal of Heart Failure

    Volume 15, Issue 9, September 2013, Pages: 1062–1073, John J. V. McMurray, Milton Packer, Akshay S. Desai, Jim Gong, Martin P. Lefkowitz, Adel R. Rizkala, Jean Rouleau, Victor C. Shi, Scott D. Solomon, Karl Swedberg, Michael R. Zile and on behalf of the PARADIGM-HF Committees and Investigators

    Version of Record online : 27 JAN 2014, DOI: 10.1093/eurjhf/hft052

  5. Pharmacokinetics and Pharmacodynamics of LCZ696, a Novel Dual-Acting Angiotensin Receptor—Neprilysin Inhibitor (ARNi)

    The Journal of Clinical Pharmacology

    Volume 50, Issue 4, April 2010, Pages: 401–414, Dr Jessie Gu, Dr Adele Noe, Dr Priya Chandra, Dr Suliman Al-Fayoumi, Dr Monica Ligueros-Saylan, Dr Ramesh Sarangapani, Dr Suzanne Maahs, Dr Gary Ksander, Dr Dean F. Rigel, Dr Arco Y. Jeng, Dr Tsu-Han Lin, Dr Weiyi Zheng and Dr William P. Dole

    Version of Record online : 7 MAR 2013, DOI: 10.1177/0091270009343932

  6. Optimizing Dose Selection with Modeling and Simulation: Application to the Vasopeptidase Inhibitor M100240

    The Journal of Clinical Pharmacology

    Volume 44, Issue 6, June 2004, Pages: 621–631, Dr. Marc Pfister, Dr. Nancy E. Martin, Dr. Lloyd P. Haskell and Dr. Jeffrey S. Barrett

    Version of Record online : 8 MAR 2013, DOI: 10.1177/0091270004265365

  7. You have free access to this content
    Independence of the blood pressure lowering effect and efficacy of the angiotensin receptor neprilysin inhibitor, LCZ696, in patients with heart failure with preserved ejection fraction: an analysis of the PARAMOUNT trial

    European Journal of Heart Failure

    Volume 16, Issue 6, June 2014, Pages: 671–677, Pardeep S. Jhund, Brian Claggett, Milton Packer, Michael R Zile, Adriaan A. Voors, Burkert Pieske, Martin Lefkowitz, Victor Shi, Toni Bransford, John J. V. McMurray and Scott D Solomon

    Version of Record online : 1 APR 2014, DOI: 10.1002/ejhf.76

  8. Treatment of Zucker diabetic fatty rats with AVE7688 improves vascular and neural dysfunction

    Diabetes, Obesity and Metabolism

    Volume 11, Issue 3, March 2009, Pages: 223–233, C. L. Oltman, E. P. Davidson, L. J. Coppey, T. L. Kleinschmidt and M. A. Yorek

    Version of Record online : 28 JUN 2008, DOI: 10.1111/j.1463-1326.2008.00924.x

  9. You have full text access to this OnlineOpen article
    Prevention against renal damage in rats with subtotal nephrectomy by sacubitril/valsartan (LCZ696), a dual-acting angiotensin receptor-neprilysin inhibitor

    Pharmacology Research & Perspectives

    Volume 5, Issue 4, August 2017, Kentaro Ushijima, Hitoshi Ando, Yusuke Arakawa, Kenichi Aizawa, Chisato Suzuki, Ken Shimada, Shu-ichi Tsuruoka and Akio Fujimura

    Version of Record online : 19 JUL 2017, DOI: 10.1002/prp2.336

  10. A Review of Vasopeptidase Inhibitors: A New Modality in the Treatment of Hypertension and Chronic Heart Failure

    Pharmacotherapy: The Journal of Human Pharmacology and Drug Therapy

    Volume 22, Issue 1, January 2002, Pages: 27–42, Surakit Nathisuwan and Robert L. Talbert

    Version of Record online : 17 JAN 2012, DOI: 10.1592/phco.22.1.27.33502

  11. Vasopeptidase inhibitors and their potential role in diabetes

    Diabetes, Obesity and Metabolism

    Volume 4, Issue 2, March 2002, Pages: 89–95, T. A. Chowdhury and T. Khan

    Version of Record online : 4 APR 2002, DOI: 10.1046/j.1463-1326.2002.00101.x

  12. You have free access to this content
    Nephroprotection in Zucker diabetic fatty rats by vasopeptidase inhibition is partly bradykinin B2 receptor dependent

    British Journal of Pharmacology

    Volume 143, Issue 1, September 2004, Pages: 27–32, Stefan Schäfer, Hans-Ludwig Schmidts, Markus Bleich, Andreas E Busch and Wolfgang Linz

    Version of Record online : 17 FEB 2009, DOI: 10.1038/sj.bjp.0705884

  13. Pharmacokinetic drug–drug interaction assessment of LCZ696 (an angiotensin receptor neprilysin inhibitor) with omeprazole, metformin or levonorgestrel-ethinyl estradiol in healthy subjects

    Clinical Pharmacology in Drug Development

    Volume 5, Issue 1, January/February 2016, Pages: 27–39, Lu Gan, Xuemin Jiang, Anisha Mendonza, Therese Swan, Christine Reynolds, Joanne Nguyen, Parasar Pal, Srikanth Neelakantham, Marion Dahlke, Thomas Langenickel, Iris Rajman, Mizuki Akahori, Wei Zhou, Sam Rebello and Gangadhar Sunkara

    Version of Record online : 4 NOV 2015, DOI: 10.1002/cpdd.181

  14. You have free access to this content
    CGS 35601, a Triple Inhibitor of Angiotensin Converting Enzyme, Neutral Endopeptidase and Endothelin Converting Enzyme

    Cardiovascular Drug Reviews

    Volume 23, Issue 4, December 2005, Pages: 317–330, Bruno Battistini, Philippe Daull and Arco Y. Jeng

    Version of Record online : 7 JUN 2006, DOI: 10.1111/j.1527-3466.2005.tb00175.x

  15. Disposition and safety of omapatrilat in subjects with renal impairment

    Clinical Pharmacology & Therapeutics

    Volume 68, Issue 3, September 2000, Pages: 261–269, Domenic A. Sica, Wei-chi Liao, Todd W. B. Gehr, Sanaulla Khan, Mohammad Jemal, Carol L. Delaney, Irene M. Ferreira and Bimal K. Malhotra

    Version of Record online : 2 SEP 2000, DOI: 10.1067/mcp.2000.109033

  16. Angiotensin-Converting Enzyme Inhibitors

    Standard Article

    Burger's Medicinal Chemistry and Drug Discovery

    Edward W. Petrillo

    Published Online : 15 SEP 2010, DOI: 10.1002/0471266949.bmc174

  17. Pharmacodynamics and Pharmacokinetics of Omapatrilat in Heart Failure

    The Journal of Clinical Pharmacology

    Volume 41, Issue 12, December 2001, Pages: 1280–1290, John B. Kostis, Marc Klapholz, Ms. Carol Delaney, Ole Vesterqvist, Marvin Cohen, James A. Manning Jr., Mohammed Jemal, Georgia D. Kollia and Dr. Wei-Chi Liao

    Version of Record online : 8 MAR 2013, DOI: 10.1177/00912700122012869

  18. You have free access to this content
    Vasopeptidase Inhibition and its Role in Congestive Heart Failure

    Congestive Heart Failure

    Volume 6, Issue 3, May/June 2000, Pages: 158–163, Domenic A. Sica

    Version of Record online : 9 OCT 2008, DOI: 10.1111/j.1527-5299.2000.80153.x

  19. Pharmacokinetic drug–drug interaction assessment between LCZ696, an angiotensin receptor neprilysin inhibitor, and hydrochlorothiazide, amlodipine, or carvedilol

    Clinical Pharmacology in Drug Development

    Volume 4, Issue 6, November/December 2015, Pages: 407–417, Hsiu-ling Hsiao, Thomas Heiko Langenickel, Michael Greeley, John Roberts, Wei Zhou, Parasar Pal, Sam Rebello, Iris Rajman and Gangadhar Sunkara

    Version of Record online : 6 MAY 2015, DOI: 10.1002/cpdd.183

  20. Oral Bioavailability and Disposition of [14C]Omapatrilat in Healthy Subjects

    The Journal of Clinical Pharmacology

    Volume 41, Issue 8, August 2001, Pages: 833–841, Bimal K. Malhotra, Ramaswamy A. Iyer, Kathy M. Soucek, Douglas Behr, Wei-chi Liao, James G. Mitroka, Sanjeev Kaul, Marvin B. Cohen and Catherine A. Knupp

    Version of Record online : 8 MAR 2013, DOI: 10.1177/00912700122010726